Price T Rowe Associates Inc Akero Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 4,321,972 shares of AKRO stock, worth $186 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
4,321,972
Previous 3,808,359
13.49%
Holding current value
$186 Million
Previous $109 Million
10.05%
% of portfolio
0.01%
Previous 0.01%
Shares
17 transactions
Others Institutions Holding AKRO
# of Institutions
212Shares Held
67.8MCall Options Held
321KPut Options Held
558K-
Rtw Investments, LP New York, NY6.86MShares$295 Million3.11% of portfolio
-
Janus Henderson Group PLC London, X06.03MShares$260 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$240 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$225 Million5.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.7MShares$159 Million0.0% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...